Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy.
Blood Glucose
/ drug effects
Cholesterol, HDL
/ blood
Cholesterol, LDL
/ blood
Diabetes Mellitus, Type 2
/ blood
Drug Therapy, Combination
/ methods
Female
Glycated Hemoglobin
/ metabolism
Humans
Hypoglycemic Agents
/ therapeutic use
Lipids
/ blood
Male
Metformin
/ therapeutic use
Middle Aged
Pioglitazone
/ therapeutic use
Sitagliptin Phosphate
/ therapeutic use
Sulfonylurea Compounds
/ therapeutic use
Thiazolidinediones
/ therapeutic use
glycemic control
lipid profile
sitagliptin
type 2 diabetes mellitus
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
29
01
2019
accepted:
08
04
2019
pubmed:
28
5
2019
medline:
13
8
2020
entrez:
28
5
2019
Statut:
ppublish
Résumé
The aim of this study was to investigate whether the effects of sitagliptin on lipid profile were maintained even after 7 years of treatment. We treated 591 patients who had not been well controlled by current therapy with the addition of sitagliptin 100 mg/d. Data were compared with those of 612 patients treated with sulfonylureas plus metformin, pioglitazone plus metformin, and pioglitazone plus sulfonylureas. We observed that, compared with patients treated with sulfonylureas plus metformin, patients receiving sitagliptin in addition to metformin experienced a greater decrease of total cholesterol and low-density lipoprotein cholesterol (LDL-C) compared with baseline and with sulfonylureas plus metformin. Compared with patients treated with metformin plus pioglitazone, sitagliptin resulted in a greater reduction of total cholesterol and LDL-C relative to baseline and to metformin plus pioglitazone. We also observed a higher increase of high-density lipoprotein cholesterol (HDL-C) after sitagliptin had been added to pioglitazone, both compared with baseline and to the competitor. Compared with patients treated with pioglitazone plus sulfonylureas, the combination of sitagliptin and sulfonylureas was more effective in reducing LDL-C and in increasing HDL-C. High-sensitivity C-reactive protein was decreased by all pharmacological combinations. We can conclude that the addition of sitagliptin led to a better and more durable improvement of lipid profile compared with sulfonylureas or thiazolidinediones.
Substances chimiques
Blood Glucose
0
Cholesterol, HDL
0
Cholesterol, LDL
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Lipids
0
Sulfonylurea Compounds
0
Thiazolidinediones
0
Metformin
9100L32L2N
Sitagliptin Phosphate
TS63EW8X6F
Pioglitazone
X4OV71U42S
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1391-1399Informations de copyright
© 2019, The American College of Clinical Pharmacology.
Références
Brand FN, Abbot RD, Kannel WB. Diabetes, intermittent claudication and risk of cardiovascular events. The Framingham study. Diabetes. 1989;38:504-509.
Capellini VK, Celotto AC, Baldo CF, et al. Diabetes and vascular disease: basis concepts of nitric oxide physiology, endothelial dysfunction, oxidative stress and therapeutic possibilities. Curr Vasc Pharmacol. 2010;8:526-544.
Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
Maffioli P, Derosa G. Sitagliptin: results from clinical practice. Curr Med Res Opin. 2013;29(11):1483-1485.
Derosa G, D'Angelo A, Maffioli P. Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. Pharmacol Res. 2015;100:127-134.
Green JB, Bethel MA, Armstrong PW, et al; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-242.
Derosa G, Ragonesi PD, Fogari E, et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. Fundam Clin Pharmacol. 2014;28(2):221-229.
Rydén L, Standl E, Bartnik M, et al; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J. 2007;28(1):88-136.
http://www.aemmedi.it/files/Linee-guida_Raccomandazioni/2007/2007-cura-diabete-mellito.pdf/. Accessed 2007.
Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol. 2006;26:2186-2191.
Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180(1):32-39.
Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. 2013;30(9):1026-1032.
Seino Y, Yabe D. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: incretin actions beyond the pancreas. J Diabetes Invest. 2013;4(2):108-130.
Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin. Relevance to diabetes mellitus. Science. 1978;200:21-27.
European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med. 1999;16:716-730.
Klose S, Borner K. Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by] Greiner Selective Analyzer (GSA II). J Clin Chem Clin Biochem. 1978;15:121-130.
Wahlefeld AW. Triglycerides determination after enzymatic hydrolysis. In: Bergmeyer HU, ed. Methods of Enzymatic Analysis. 2nd English ed. New York: Academic Press; 1974: 18-31.
Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955;34:1345-1353.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem. 1999;45(12):2136-2141.
Winer BJ. Statistical Principles in Experimental Design. 2nd ed, New York: McGraw-Hill; 1971.
Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29(1):14-25.
Giampietro O, Giampietro C, Bartola LD, Masoni MC, Matteucci E. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes. Drug Des Devel Ther. 2013;7:99-104.
Derosa G, D'Angelo A, Salvadeo SA, et al. Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. Microvasc Res. 2010;79(2):144-149.